Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10634922rdf:typepubmed:Citationlld:pubmed
pubmed-article:10634922lifeskim:mentionsumls-concept:C0013264lld:lifeskim
pubmed-article:10634922lifeskim:mentionsumls-concept:C0002520lld:lifeskim
pubmed-article:10634922lifeskim:mentionsumls-concept:C0017797lld:lifeskim
pubmed-article:10634922lifeskim:mentionsumls-concept:C0205224lld:lifeskim
pubmed-article:10634922pubmed:issue6lld:pubmed
pubmed-article:10634922pubmed:dateCreated2000-6-6lld:pubmed
pubmed-article:10634922pubmed:abstractTextTo determine whether whole body protein kinetics are altered in Duchenne muscular dystrophy (DMD), six 9 +/- 1-year-old children with DMD and five weight and height matched controls, received intravenous infusion of L-[1-(13)C]leucine and L-[2-(15)N]glutamine in the post-absorptive state. Glutamine rate of appearance was approximatly 24% lower in DMD boys than in controls (321 +/- 22 vs 425 +/- 37 micromol kg(-1)h(-1), P< 0.05) resulting from a 32% decrease in glutamine de novo synthesis (230 +/- 21 vs 340 +/- 34 micromol kg(-1)h(-1), P< 0.05). Whereas there was no difference between groups in estimates of protein degradation and synthesis, leucine oxidation rate was 44% higher in DMD boys than in controls (23 +/- 2 vs 16 +/- 2 micromol kg(-1)h(-1), P< 0.05). The data suggest that the dramatic mucle mass loss observed in DMD boys is associated with a) significant protein wasting, since increased leucine oxidation reflects a more negative whole body leucine balance, and b) a significant decrease in glutamine availability in the postabsorptive state. Glutamine might therefore be a 'conditionally essential' amino-acid in DMD.lld:pubmed
pubmed-article:10634922pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10634922pubmed:languageenglld:pubmed
pubmed-article:10634922pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10634922pubmed:citationSubsetIMlld:pubmed
pubmed-article:10634922pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10634922pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10634922pubmed:statusMEDLINElld:pubmed
pubmed-article:10634922pubmed:monthDeclld:pubmed
pubmed-article:10634922pubmed:issn0261-5614lld:pubmed
pubmed-article:10634922pubmed:authorpubmed-author:HammondDDlld:pubmed
pubmed-article:10634922pubmed:authorpubmed-author:HaymondMMlld:pubmed
pubmed-article:10634922pubmed:authorpubmed-author:MaurasNNlld:pubmed
pubmed-article:10634922pubmed:authorpubmed-author:HankardRRlld:pubmed
pubmed-article:10634922pubmed:authorpubmed-author:DarmaunDDlld:pubmed
pubmed-article:10634922pubmed:copyrightInfoCopyright 1999 Harcourt Publishers Ltd.lld:pubmed
pubmed-article:10634922pubmed:issnTypePrintlld:pubmed
pubmed-article:10634922pubmed:volume18lld:pubmed
pubmed-article:10634922pubmed:ownerNLMlld:pubmed
pubmed-article:10634922pubmed:authorsCompleteYlld:pubmed
pubmed-article:10634922pubmed:pagination365-9lld:pubmed
pubmed-article:10634922pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:10634922pubmed:meshHeadingpubmed-meshheading:10634922...lld:pubmed
pubmed-article:10634922pubmed:meshHeadingpubmed-meshheading:10634922...lld:pubmed
pubmed-article:10634922pubmed:meshHeadingpubmed-meshheading:10634922...lld:pubmed
pubmed-article:10634922pubmed:meshHeadingpubmed-meshheading:10634922...lld:pubmed
pubmed-article:10634922pubmed:meshHeadingpubmed-meshheading:10634922...lld:pubmed
pubmed-article:10634922pubmed:meshHeadingpubmed-meshheading:10634922...lld:pubmed
pubmed-article:10634922pubmed:meshHeadingpubmed-meshheading:10634922...lld:pubmed
pubmed-article:10634922pubmed:meshHeadingpubmed-meshheading:10634922...lld:pubmed
pubmed-article:10634922pubmed:meshHeadingpubmed-meshheading:10634922...lld:pubmed
pubmed-article:10634922pubmed:meshHeadingpubmed-meshheading:10634922...lld:pubmed
pubmed-article:10634922pubmed:meshHeadingpubmed-meshheading:10634922...lld:pubmed
pubmed-article:10634922pubmed:meshHeadingpubmed-meshheading:10634922...lld:pubmed
pubmed-article:10634922pubmed:year1999lld:pubmed
pubmed-article:10634922pubmed:articleTitleIs glutamine a 'conditionally essential' amino acid in Duchenne muscular dystrophy?lld:pubmed
pubmed-article:10634922pubmed:affiliationNemours Children's Clinic, Jacksonville, Florida, USA.lld:pubmed
pubmed-article:10634922pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10634922pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10634922pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10634922lld:pubmed